The lancet oncology
The most recent articles from:
Lancet Oncol.
-
The lancet oncology · Aug 2019
The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis.
The fragility index of trial results-ie, the minimum number of changes from non-events to events resulting in loss of statistical significance-can provide a measure of confidence that a positive effect reported in a randomised controlled trial is real. We aimed to calculate the fragility index of randomised controlled trials supporting US Food and Drug Administration (FDA)-approved anticancer drugs. ⋯ None.